AstraZeneca announced that the U.S. Food and Drug Administration has approved its fixed-duration all-oral combination of Calquence® (acalabrutinib) with venetoclax for the first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults. The approval marks the first time a Bruton’s tyrosine kinase (BTK) inhibitor-based regimen has been authorised in the U.S. as a time-limited, oral treatment option for newly diagnosed patients.

Sai Life Sciences Limited has announced an ambitious recruitment drive to hire more than 700 scientific, technical and management professionals in the 2026–27 financial year as it scales up operations to meet growing global demand for drug discovery, development and manufacturing services.